Pharma-Bio Serv (PBSV) Total Non-Current Liabilities (2017 - 2025)

Pharma-Bio Serv (PBSV) has reported Total Non-Current Liabilities for 9 consecutive years, with $1.7 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $1.7 million; the trailing twelve-month figure through Jul 2025 stood at $1.7 million (changed N/A YoY), and the FY2024 full-year result was $1.9 million, changed N/A from the prior year.
• Total Non-Current Liabilities retreated to $1.7 million in Q3 2025 per PBSV's latest filing, from $1.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $8.9 million in Q1 2021 and bottomed at $1.7 million in Q3 2025.
• Historically, Total Non-Current Liabilities has averaged $3.9 million across 5 years, with a median of $4.2 million in 2022.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities soared 77.42% in 2021, then slumped 50.81% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $5.0 million in 2021, then sank by 50.81% to $2.5 million in 2022, then rose by 9.34% to $2.7 million in 2023, then dropped by 28.6% to $1.9 million in 2024, then fell by 13.42% to $1.7 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.7 million, $1.8 million, and $1.9 million for Q3 2025, Q2 2025, and Q4 2024 respectively.